Primary Immunodeficiency (PID) — Subcutaneous Ig NextGen 16% in PID Patients
Citation(s)
A Multi-centre, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Subcutaneous Infusions of Ig NextGen 16% in Patients With Primary Immunodeficiency (PID).